loading page

Tocilizumab-induced Cytomegalovirus Colitis in a Patient with COVID-19
  • +4
  • Mohamad Khatib,
  • Karimulla Shaik,
  • Amna Ahmed,
  • Mohammad Alwraidat,
  • Ahmed soliman Mohamed,
  • mohamed aboukamar,
  • Abdulqadir Nashwan
Mohamad Khatib
Hamad Medical Corporation
Author Profile
Karimulla Shaik
Hamad Medical Corporation
Author Profile
Amna Ahmed
Hamad Medical Corporation
Author Profile
Mohammad Alwraidat
Hamad Medical Corporation
Author Profile
Ahmed soliman Mohamed
Hamad Medical Corporation
Author Profile
mohamed aboukamar
Hamad Medical Corporation
Author Profile
Abdulqadir Nashwan
Hamad Medical Corporation
Author Profile

Abstract

Cytomegalovirus (CMV) infection exists in 50-80% of the world’s population in clinically undetected form due to their immunocompetent status. Here we report a case of a 42-year-old COVID-19 patient with no past medical history, who received tocilizumab, which led to a massive lower gastrointestinal bleeding not responded to medical management.

Peer review status:Published

13 Aug 2020Submitted to Clinical Case Reports
18 Aug 2020Submission Checks Completed
18 Aug 2020Assigned to Editor
24 Aug 2020Reviewer(s) Assigned
25 Aug 2020Review(s) Completed, Editorial Evaluation Pending
07 Sep 2020Editorial Decision: Revise Minor
24 Sep 20201st Revision Received
26 Sep 2020Submission Checks Completed
26 Sep 2020Assigned to Editor
26 Sep 2020Review(s) Completed, Editorial Evaluation Pending
12 Oct 2020Editorial Decision: Accept
Jan 2021Published in Clinical Case Reports volume 9 issue 1 on pages 148-152. 10.1002/ccr3.3487